Dr. Daniel H. Ahn, DO

Dr. Ahn practices at Mayo Clinic Ambulatory Surgery Center - Scottsdale in Scottsdale, Arizona.

Dr. Ahn's NPI, 1669633897, was assigned on June 20, 2008. Dr. Ahn graduated from Texas College of Osteopathic Medicine in 2008. Dr. Ahn holds Arizona license 006924.

Dr. Ahn's primary practice is Mayo Clinic Ambulatory Surgery Center - Scottsdale, at 13400 East Shea Boulevard, Scottsdale, AZ 85259. The practice phone is (480) 342-4201.

Dr. Ahn's primary practice is Mayo Clinic Ambulatory Surgery Center - Scottsdale in Scottsdale, Arizona. Dr. Ahn is also affiliated with Mayo Clinic Hospital - Phoenix. The medical group on file is Mayo Clinic Arizona. Dmand AI also links Dr. Ahn to 1 more medical group, named with a free account. Dr. Ahn's employer is on file too: a surgery center (asc).

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ahn practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Ahn's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Ahn is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Ahn's licenses on file in 2 states: Arizona and Texas.

Dmand AI lists breast cancer, chronic anemia, colorectal cancer, lung cancer, lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Ahn treats.

CMS data shows 49,453 Medicare services from Dr. Ahn across 43 procedure codes in 2024, for 680 Medicare patients. Medicare paid $1,263,270 for them.

CMS counts 680 Medicare patients who saw Dr. Ahn in 2024. The largest group is 65 to 74, with 333 patients. 70% of them have high blood pressure, and 70% have high cholesterol. 4% are also on Medicaid. Their average risk score is 2.46, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ahn's median patient age at 71, with 52% women.

In 2024, Dr. Ahn wrote 388 Medicare Part D claims for 84 patients. 76% of them were for generic drugs. CMS names the drug for 242 of them, across 8 drugs with 11 or more claims each, at $243,476 in total drug cost. In 2023, CMS named 97 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Ahn for performance year 2024, reported as part of a group. Dr. Ahn accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ahn as offering telehealth.

Dmand AI links 89 papers to Dr. Ahn, published from 2009 to 2025. 2021 was the busiest year, with 10. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Biliary Tract Neoplasms and Colorectal Neoplasms. Dr. Ahn has published most often in Cancers (Basel). Dr. Ahn's most frequent co-authors are Tanios S. Bekaii-Saab, MD, Mohamad Bassam Sonbol, MD and Mitesh J. Borad, MD.

Dmand AI links Dr. Ahn to 5 clinical trials, 2 of them phase 1 studies. Conditions studied include Bile Duct Neoplasms, Gallbladder Neoplasms and Klatskin Tumor.

CMS Open Payments shows 183 general payments to Dr. Ahn from 24 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 56% of the total. Exelixis Inc. paid the most, $30,043. It also lists 3 research payments totaling $1,210 in 2017.

Dmand AI lists 2 awards for Dr. Ahn, most recently ASCO GI Symposium Merit Award in 2016.

Dr. Ahn graduated from Texas College of Osteopathic Medicine in 2008. Dr. Ahn is a member of AACR, AMA and ASCO.

Dr. Ahn is in network with 7 carriers, including Excellus BlueCross BlueShield, United Healthcare and Aetna. PPO plans come from the most carriers, 4. Check the plan with the practice before a visit.